McLoughlin J C, Buchanan K D, Alam M J
Lancet. 1979 Sep 22;2(8143):603-5. doi: 10.1016/s0140-6736(79)91665-9.
BAY g 5421, a glycoside-hydrolase inhibitor, produced symptomatic improvement in ten patients with the dumping syndrome. 100 mg BAY g 5421, given before a 50 g sucrose meal, produced pronounced attenuation of both hyperglycaemic and hypoglycaemic phases of plasma glucose levels; and it greatly reduced the rise in plasma levels of gastric inhibitory polypeptide and insulin. Gastric emptying, studied simultaneously by an isotopic method, showed little difference between tests, suggesting that the improvement achieved was not mediated by slowing gastric emptying.
BAY g 5421是一种糖苷水解酶抑制剂，可使10例倾倒综合征患者的症状得到改善。在摄入50g蔗糖餐之前服用100mg BAY g 5421，可显著减轻血糖水平的高血糖期和低血糖期；并大大降低了血浆中胃抑制多肽和胰岛素水平的升高。同时用同位素方法研究胃排空，结果显示各试验之间差异不大，这表明所取得的改善并非由胃排空减慢介导。
